*Some Market data delayed by 15 mins.

Akebia Therapeutics, Inc.

Symbol: AKBA (NASDAQ)
1.17 ▲ (1.74%) 0.020

Company Description:
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Key Stats
  • Today's Open: $1.14
  • Today's High: $1.195
  • Today's Low: $1.125
  • Today's Volume: 2.38M
  • Yesterday Close: $1.15
  • Yesterday High: $1.18
  • Yesterday Low: $1.12
  • Yesterday Volume: 2.39M
  • Last Min Volume: 19
  • Last Min High: $1.17
  • Last Min Low: $1.17
  • Last Min VWAP: $1.17
Company Profile
  • Name: Akebia Therapeutics, Inc.
  • Website: https://www.akebia.com
  • Listed Date: 2014-03-20
  • Location: CAMBRIDGE, MA
  • Market Status: Active
  • CIK Number: 0001517022
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $241.04M
  • Round Lot: 100
  • Outstanding Shares: 209.60M
  • Asset Type: CS
RECENT FILINGS FOR AKBA
Filing DateFiling TypeFormat
2024-05-144View
2024-05-144View
2024-05-13144View
2024-05-13144View
2024-05-094View
2024-05-0910-QView
2024-05-098-KView
2024-04-25ARSView
2024-04-25DEFA14AView
2024-04-25DEF 14AView
2024-04-238-KView
2024-04-168-KView
2024-03-288-KView
2024-03-158-KView
2024-03-1410-KView
2024-03-148-KView
2024-03-014View
2024-03-014View
2024-03-014View
2024-03-014View
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.